HUTCHMED Receives Approval to Commercialize ELUNATE® in

First homegrown innovative medicine approved in Macau based on China clinical data...

Related Keywords

China ,Australia ,Japan ,Macau Special Administrative Region ,Macau General ,Macau ,United States ,South Korea ,Chinese ,Japanese ,American ,Korea ,Karen Atkin ,Linkedin ,Fruquintinib Development ,Drug Administration ,Beigene Ltd ,Data Monitoring Committee ,Nasdaq ,Journal Of The American Medical Association ,Chinese Society Of Clinical Oncology Annual Meeting ,American Society Of Clinical Oncology Annual Meeting ,Japanese Pharmaceuticals ,European Medicines Agency ,National Medical Products Administration ,China National Reimbursement Drug List ,Devices Agency ,Innovent Biologics Inc ,Macau Special Administrative ,Mainland China ,Chief Operating Officer ,Fruquintinib Approval ,American Medical Association ,Fast Track Designation ,New Drug Application ,Medical Devices Agency ,Independent Data Monitoring Committee ,Innovent Biologics ,Clinical Oncology Annual Meeting ,Chinese Society ,Nasdaq Hcm ,Hutchmed China Limited ,